• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 3:51:24 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    SC 13G/A 1 durect13ga1-021221.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 1)1
     
    Durect Corporation
    (Name of Issuer)
    Common Stock, $0.0001 par value
    (Title of Class of Securities)
    266605104
    (CUSIP Number)
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     ☒
    Rule 13d-1(b)
     
     ☐
    Rule 13d-1(c)
     
     ☐
    Rule 13d-1(d)
     
     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT CAPITAL, LP
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    17,730,680
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    8.0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IA, PN
     
     



                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT MASTER, LP
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    CAYMAN ISLANDS
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    - 0 -
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    PN
     
     



     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT HOLDINGS GP, LLC
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    17,730,680
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    8.0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    OO
     
     



     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    LION POINT CAPITAL GP, LLC
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    - 0 -
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    OO
     
     



     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    DIDRIC CEDERHOLM
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    SWEDEN AND FRANCE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    17,730,680
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    8.0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IN
     
     


     
                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    JAMES FREEMAN
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☐
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    USA
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    - 0 -
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    17,730,680
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    - 0 -
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    17,730,680
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    8.0%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IN
     
     



     
    Item 1(a).
    Name of Issuer:
     
    Durect Corporation (the “Issuer”).
     
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    10260 Bubb Road, Cupertino, California 95014
     
    Item 2(a).
    Name of Persons Filing:

    This Amendment No. 1 to Schedule 13G (“Amendment No. 1”) is being jointly filed by Lion Point Master, LP, a Cayman Islands exempted limited partnership (“Lion Point Master”), Lion Point Capital GP, LLC, a Delaware limited liability company (“Lion Point GP”), Lion Point Capital, LP, a Delaware limited partnership (“Lion Point Capital”), Lion Point Holdings GP, LLC, a Delaware limited liability company (“Lion Point Holdings”), Didric Cederholm, a dual citizen of Sweden and France, and James Freeman, a citizen of the United States of America. Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”
    Lion Point Holdings is the general partner of Lion Point Capital. Lion Point Capital is the investment manager to Lion Point Master.  Lion Point GP is the general partner of Lion Point Master. Mr. Cederholm is a Founding Partner and Chief Investment Officer of each of Lion Point GP and Lion Point Capital. Mr. Cederholm is also a Member and a Manager of each of Lion Point GP and Lion Point Holdings. Mr. Freeman is a Founding Partner and Head of Research of each of Lion Point GP and Lion Point Capital. Mr. Freeman is also a Member and a Manager of each of Lion Point GP and Lion Point Holdings. By virtue of these relationships, each of Lion Point Holdings, Mr. Cederholm and Mr. Freeman may be deemed to beneficially own the securities beneficially owned by Lion Point Capital.
     
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The principal business office of each of the Reporting Persons is 250 West 55th Street, 33rd Floor, New York New York 10019.
     
    Item 2(c).
    Citizenship:

    Lion Point Master is organized under the laws of the Cayman Islands. Each of Lion Point GP, Lion Point Capital, and Lion Point Holdings is organized under the laws of the State of Delaware. Mr. Cederholm is a dual citizen of Sweden and France. Mr. Freeman is a citizen of the United States of America.
     
    Item 2(d).
    Title of Class of Securities:

    Common Stock, $0.0001 par value (the “Shares”)
     
    Item 2(e).
    CUSIP Number:

    266605104

     
    Item 3.
    If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    / /
    Not Applicable
    (a)
    / /
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)
    / /
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    / /
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    / /
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    / /
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).*
    (f)
    / /
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
    (g)
    / /
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).**
    (h)
    / /
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    / /
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
    (j)
    / /
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
    (k)
    / /
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).

     
     
    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer.

    (a)
    Amount beneficially owned:
    As of the close of business on December 31, 2020, each of Lion Point Capital, Lion Point Holdings, Mr. Cederholm and Mr. Freeman may be deemed to have  beneficially owned 17,730,680 shares of Common Stock. As of the close of business on December 31, 2020, each of Lion Point Master and Lion Point GP may be deemed to have beneficially owned 0 shares of Common Stock.

    (b)
    Percent of class:
    As of the close of business on December 31, 2020, each of Lion Point Capital, Lion Point Holdings, Mr. Cederholm and Mr. Freeman may be deemed to have beneficially owned 8.0% (based upon 220,883,514 Shares outstanding, which is the total number of Shares to be outstanding following the offering described in the Issuer’s Prospectus Supplement filed on Form 424B5 with the Securities and Exchange Commission on February 5, 2021). As of the close of business on December 31, 2020, each of Lion Point Master and Lion Point GP may be deemed to have beneficially owned 0%.
    (c)            Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:
    See Cover Pages Items 5-9.

     (ii)
    Shared power to vote or to direct the vote
    See Cover Pages Items 5-9.

     (iii)
    Sole power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.

     (iv)
    Shared power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.
    The filing of this Amendment No. 1 shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that are not directly owned by such Reporting Person.

     
    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof each reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.

    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2020
     
    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.
     
    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.



    SIGNATURES
    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information with respect to it or him set forth in this statement is true, complete and correct.
    Dated: February 12, 2021
     
     
     
     
    LION POINT MASTER, LP
     
     
     
    By:
    Lion Point Capital GP, LLC,
    its General Partner
     
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
     
    LION POINT CAPITAL GP, LLC
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
     
    LION POINT CAPITAL, LP
     
     
     
    By:
    Lion Point Holdings GP, LLC,
    its General Partner
     
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
     
    LION POINT HOLDINGS GP, LLC
     
     
     
    By:
    /s/ Didric Cederholm
     
     
    Name:
    Didric Cederholm
     
     
    Title:
    Manager and Member

     
     
     
     
    /s/ Didric Cederholm
     
     
    DIDRIC CEDERHOLM

     
     
     
     
    /s/ James Freeman
     
     
    JAMES FREEMAN

    Get the next $DRRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Financials

    Live finance-specific insights

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

      -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

      11/13/24 4:01:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DURECT Corporation

      SC 13G/A - DURECT CORP (0001082038) (Subject)

      11/19/24 5:10:25 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      3/27/24 3:15:14 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      2/16/24 4:09:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Durect with a new price target

      HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

      5/5/21 6:31:29 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Durect with a new price target

      Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      2/3/21 8:15:53 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

      5/13/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POSIMIR

      Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

      2/2/21 7:24:30 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

      CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

      3/21/23 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

      CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

      7/5/22 8:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by DURECT Corporation

      10-Q - DURECT CORP (0001082038) (Filer)

      5/14/25 4:05:35 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DURECT CORP (0001082038) (Filer)

      5/13/25 4:15:17 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by DURECT Corporation

      10-K - DURECT CORP (0001082038) (Filer)

      3/27/25 5:26:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Sussman Norman

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:47:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Papp Timothy M.

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:46:24 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Brown James E

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:42:29 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care